Netrin-1 and Placenta Accreta
The Implication of Placental Netrin-1 Receptor DCC in the Pathophysiology of Placenta Accreta
1 other identifier
interventional
34
1 country
1
Brief Summary
Netrin-1 is a secreted protein, which was first identified as a neuronal guidance factor. It is expressed in a multitude of tissues as pancreas, lung, breast, and placenta. Netrin-1 is a multifunctional protein, involved in cell polarity, adhesion, angiogenesis, apoptosis, migration, morphogenesis, and differentiation of various cell types. Most of netrin-1 activity occur through signaling pathways induced by its two main receptors, DCC (deleted in colorectal cancer) and UNC5H (uncoordinated-5 homolog). Its receptors have been linked to the processes of apoptosis and angiogenesis. In absence of netrin-1, DCC and UNC5H receptors lead to apoptosis. In contrary, in presence of netrin-1, receptors transduce molecular cascades leading to proliferation, differentiation and migration of the cells. Netrin-1 has been involved in the pathogenesis of multiple diseases, as diabetes, cardiovascular diseases, and cancer. Serum Netrin-1 levels were high in preeclamptic patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 21, 2020
CompletedFirst Posted
Study publicly available on registry
December 24, 2020
CompletedStudy Start
First participant enrolled
December 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2022
CompletedAugust 22, 2022
August 1, 2022
6 months
December 21, 2020
August 19, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Placental Netrin-1 level
will be measured by using enzyme-linked immunosorbent assay (ELİSA) in placental homogenate
4 weeks
Study Arms (2)
Normal pregnancy group
OTHERPlacenta accreta group
OTHERInterventions
Pregnant women at gestational age 28-32 weeks
Eligibility Criteria
You may qualify if:
- Age between 20-40 years.
- Singleton pregnancy.
- Women with suspicion of PA by two-dimensional (2D) gray scale imaging and color Doppler flow mapping
You may not qualify if:
- Multiple pregnancy,
- Fetal anomalies,
- Preterm premature rupture of membranes, or infection
- Any medical disorders, such as thyroid dysfunction, hypertension, and gestational diabetes
- Patients with known bleeding disorders or on anticoagulant therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Woman's Health Hospital
Asyut, 71111, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
December 21, 2020
First Posted
December 24, 2020
Study Start
December 1, 2021
Primary Completion
June 1, 2022
Study Completion
June 1, 2022
Last Updated
August 22, 2022
Record last verified: 2022-08